Staphylococcus Aureus and The Skin Microbiome During Flare And Resolution Of Atopic Dermatitis
Status:
Not yet recruiting
Trial end date:
2023-05-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to compare and evaluate in patients with atopic
dermatitis. The main questions it aims to answer are:
- Does the addition of systemic dicloxacillin to TCS treatment result in a more rapid and
deeper treatment response?
- Does the addition of systemic dicloxacillin to TCS treatment affect the skin microbiome,
the skin barrier and immune response during improvement of AD?
- Does topical application of S. aureus or SEB increase the severity and rapidity of a
flare?
Participants will meet for two different phases:
- Phase one will be at randomized controlled trial where patients are randomized to either
systemic dicloxacillin + mometasone furoate or placebo + mometasone furoate.
- Phase II: Patients will meet for five visits to receive different solutions on the skin
including autologous s. aureus and staphylococcal enterotoxin B.